Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Interplay of Proteostasis Capacity and Protein Aggregation: Implications for Cellular Function and Disease
Mark S. Hipp, F. Ulrich Hartl
Journal of Molecular Biology (2024) Vol. 436, Iss. 14, pp. 168615-168615
Open Access | Times Cited: 16
Exploring the IRE1 interactome: From canonical signaling functions to unexpected roles
Simon Le Goupil, Hadrien Laprade, Marc Aubry, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 4, pp. 107169-107169
Open Access | Times Cited: 11
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer
Longyong Xu, Fanglue Peng, Qin Luo, et al.
Cell (2024)
Closed Access | Times Cited: 7
Homeostasis control in health and disease by the unfolded protein response
Diego Acosta‐Alvear, Jonathan M. Harnoss, Peter Walter, et al.
Nature Reviews Molecular Cell Biology (2024)
Closed Access | Times Cited: 7
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance
Jameela Lokhandwala, Tracess Smalley, Timothy H. Tran
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
UFMylation: An integral post-translational modification for the regulation of proteostasis and cellular functions
Xiaohui Wang, Xiaowei Lv, Jingjing Ma, et al.
Pharmacology & Therapeutics (2024) Vol. 260, pp. 108680-108680
Closed Access | Times Cited: 4
CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment
Haiyan Xu, Shengbai Xue, Yang Sun, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010029-e010029
Open Access
Chaperone Directed Heterobifunctional Molecules Circumvent Krasg12c Inhibitor Resistance
Takeshi Shimamura, Inés Pulido, Qiyue Luan, et al.
(2025)
Closed Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Requirements for nuclear GRP78 transcriptional regulatory activities and interaction with nuclear GRP94
Ze Liu, Dat P. Ha, Liangguang Leo Lin, et al.
Journal of Biological Chemistry (2025), pp. 108369-108369
Open Access
Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer
Krishnan K. Mahadevan, Antonio Maldonado, Bingrui Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
SOS1 inhibitor BI-3406 shows in vivo antitumor activity akin to genetic ablation and synergizes with a KRAS G12D inhibitor in KRAS LUAD
Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 11
Open Access
Tumor‐Selective Gene Therapy: Using Hairpin DNA Oligonucleotides to Trigger Cleavage of Target RNA by Endogenous flap endonuclease 1 (FEN 1) Highly Expressed in Tumor Cells
Chunlu Wang, Chen Wang, Chijie Xiao, et al.
Small (2025)
Closed Access
Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
H. Y. Shin, S. O. Hwang, Jeong Hyun Jeong, et al.
Pharmacological Research (2025), pp. 107722-107722
Open Access
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.
Inés Pulido, Qiyue Luan, Sara Pastor-Puente, et al.
Cancer Letters (2025), pp. 217691-217691
Open Access
A nonenzymatic dependency on inositol-requiring enzyme 1 controls cancer cell cycle progression and tumor growth
Iratxe Zuazo-Gaztelu, David A. Lawrence, Ioanna Oikonomidi, et al.
PLoS Biology (2025) Vol. 23, Iss. 4, pp. e3003086-e3003086
Open Access
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
Beyond First-Generation KRAS Inhibitors: BBO-8520 Tests the Dual Mechanism Hypothesis
Zhiwei Zhou, Kenneth D. Westover
Cancer Discovery (2025) Vol. 15, Iss. 3, pp. 455-457
Closed Access
Unconventional strategy could be the future: From target to KRAS broad range treatment
Sara Fancelli, Giulia Petroni, Serena Pillozzi, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29739-e29739
Open Access | Times Cited: 3
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex
Andreas Damianou, Zhu Liang, Frederik Lassen, et al.
Life Science Alliance (2024) Vol. 7, Iss. 5, pp. e202302245-e202302245
Open Access | Times Cited: 2
Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, et al.
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 298-314
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top